GTX Genetix Grp

RNS Number:7527P
Genetix Group PLC
10 January 2002

         Genetix Group plc licenses microarray scanner technology for
                           gene expression analysis



New Milton, UK, 10 January 2002 -- Genetix Group plc (LSE: GTX), the genomics
and proteomics technology group, today announces that it has signed a
licensing agreement with Biomedical Photometrics Inc. (Waterloo, Canada) for
the rights to manufacture and sell microarray scanners covered by its patented
technology. The aQuire scanners will be used to read molecular biological
based arrays including DNA microarrays.  Companies use gene expression
profiles for the identification and validation of potential drug targets.



The scanners will complement the arraying robots already manufactured by
Genetix, allowing the company to sell complete systems for gene expression
analysis.  Genetix will provide two systems: a high throughput array making
and analysis system based upon the well established QArray and the new aQuire
confocal scanner; and a second system using the new smaller QArray Mini and
the aQuire Mini scanner.



Dr Julian Burke, Chief Scientific Officer of Genetix, said:



"We are very excited about this new opportunity to extend our product range
into the area of high value data acquisition applications.  In particular, the
packaging of our new aQuire scanner and QArray Mini will be a potent
combination in this market, facilitating the introduction of arrays into many
laboratories that may have previously considered the technology to be beyond
their reach".



Enquiries:


Genetix Group plc                                 Tel: 01425 624600
Mark Reid, Chief Executive
Gary Corsi, Finance Director


Financial Dynamics           Tel: 07747 602 739/020 7831 3113
Sarah Mehanna



Notes to Editors

About Genetix Group plc

Genetix Group plc provides automated systems and services for genomic and
proteomic research. It supplies many leading academic institutions world-wide
including the Max Planck Institute and major international companies involved
in the drug discovery process including GSK, AstraZeneca and Novartis. Genetix
made a significant contribution to the Human Genome Project by supplying
high-throughput equipment to seven of the leading eight laboratories of the
consortia. Genetix through its R&D expertise and scientific resource is
committed to the continual development of innovative solutions to accelerate
the rate of global scientific discovery. Genetix is quoted on the London Stock
Exchange and is based in New Milton Hampshire, UK.

Genetix Grp (LSE:GTX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Genetix Grp (LSE:GTX)
Historical Stock Chart
From Jul 2023 to Jul 2024